# SCIMITAR (NCT03541850)

> Stereotactic Body Radiation Therapy in Treating Patients With Localized Prostate Cancer That Have Undergone Surgery

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03541850
- Phase: PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Jonsson Comprehensive Cancer Center
- Conditions: PSA Level Greater Than 0.03; PSA Progression; Stage I Prostate Adenocarcinoma AJCC (American Joint Committee on Cancer ) v7; Stage II Prostate Adenocarcinoma AJCC v7; Stage III Prostate Adenocarcinoma AJCC v7
- Interventions: Antiandrogen Therapy; Quality-of-Life Assessment; Stereotactic Body Radiation Therapy
- Enrollment: 92
- Primary outcome: Biochemical recurrence-free survival (BCRFS)
- Primary outcome: Physician-scored toxicity
- Primary outcome: Patient-reported toxicity outcomes EPIC-26
- Primary outcome: Patient-reported toxicity outcomes IPSS

## Indexed commentary on SCIMITAR so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 12
- YouTube: 1
- X videos: 1

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=scimitar-nct03541850

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03541850", "email": "<work email>"}; the inbox owner confirms by the emailed link.